Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

OKYO Pharma reports quality-of-life breakthrough for urcosimod in nerve pain trial

KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).

Leia mais: OKYO Pharma reports quality-of-life breakthrough for urcosimod in nerve pain trial